Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Chiasserini

Showing results (11-20 of 88) with videos related to

Pageof 9
Sort By:
Journal of Alzheimer'S Disease : JAD|October 9, 2010
CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's diseaseDavide Chiasserini, Lucilla Parnetti, Ulf Andreasson, et al.
Cancers|November 13, 2021
A Prostate Cancer Proteomics Database for SWATH-MS Based Protein QuantificationAmmara Muazzam, Davide Chiasserini, Janet Kelsall, et al.
Haematologica|October 11, 2015
Cytoskeletal perturbation leads to platelet dysfunction and thrombocytopenia in variant forms of Glanzmann thrombastheniaLoredana Bury, Emanuela Falcinelli, Davide Chiasserini, et al.
Nature Communications|January 3, 2025
Immunoassay detection of multiphosphorylated tau proteoforms as cerebrospinal fluid and plasma Alzheimer's disease biomarkersAnna L Wojdała, Giovanni Bellomo, Lorenzo Gaetani, et al.
Neurobiology of Disease|December 24, 2025
Cerebrospinal fluid α-synuclein seed amplification assay positivity is associated with increased plasma neurofilament light chain in Alzheimer's diseaseGiovanni Bellomo, Andrea Toja, Lorenzo Gaetani, et al.
Nature Reviews. Neurology|February 20, 2013
Cerebrospinal fluid biomarkers in Parkinson diseaseLucilla Parnetti, Anna Castrioto, Davide Chiasserini, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 8, 2017
Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson's disease: A systematic review and meta-analysisPaolo Eusebi, David Giannandrea, Leonardo Biscetti, et al.
Molecular Neurodegeneration|September 9, 2016
No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSFClaudia Cicognola, Davide Chiasserini, Paolo Eusebi, et al.
Journal of Alzheimer'S Disease : JAD|July 5, 2022
Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical ValidationAnna Lidia Wojdała, Davide Chiasserini, Giovanni Bellomo, et al.
BMJ Open|June 15, 2016
Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysisPaolo Eusebi, David Giannandrea, Leonardo Biscetti, et al.
Pageof 9

Showing results (11-20 of 88) with videos related to

Sort By:
Pageof 9
Journal of Alzheimer'S Disease : JAD|October 9, 2010
CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's diseaseDavide Chiasserini, Lucilla Parnetti, Ulf Andreasson, et al.
Cancers|November 13, 2021
A Prostate Cancer Proteomics Database for SWATH-MS Based Protein QuantificationAmmara Muazzam, Davide Chiasserini, Janet Kelsall, et al.
Haematologica|October 11, 2015
Cytoskeletal perturbation leads to platelet dysfunction and thrombocytopenia in variant forms of Glanzmann thrombastheniaLoredana Bury, Emanuela Falcinelli, Davide Chiasserini, et al.
Nature Communications|January 3, 2025
Immunoassay detection of multiphosphorylated tau proteoforms as cerebrospinal fluid and plasma Alzheimer's disease biomarkersAnna L Wojdała, Giovanni Bellomo, Lorenzo Gaetani, et al.
Neurobiology of Disease|December 24, 2025
Cerebrospinal fluid α-synuclein seed amplification assay positivity is associated with increased plasma neurofilament light chain in Alzheimer's diseaseGiovanni Bellomo, Andrea Toja, Lorenzo Gaetani, et al.
Nature Reviews. Neurology|February 20, 2013
Cerebrospinal fluid biomarkers in Parkinson diseaseLucilla Parnetti, Anna Castrioto, Davide Chiasserini, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 8, 2017
Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson's disease: A systematic review and meta-analysisPaolo Eusebi, David Giannandrea, Leonardo Biscetti, et al.
Molecular Neurodegeneration|September 9, 2016
No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSFClaudia Cicognola, Davide Chiasserini, Paolo Eusebi, et al.
Journal of Alzheimer'S Disease : JAD|July 5, 2022
Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical ValidationAnna Lidia Wojdała, Davide Chiasserini, Giovanni Bellomo, et al.
BMJ Open|June 15, 2016
Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysisPaolo Eusebi, David Giannandrea, Leonardo Biscetti, et al.
Pageof 9